Immuno-Oncology Drugs Market Report 2026

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $120.37 billion in 2025 to $136.15 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to limited availability of immuno-oncology drugs, reliance on conventional chemotherapy, increasing prevalence of cancers like melanoma and lung cancer, growing oncology-focused research initiatives, early regulatory approvals for monoclonal antibodies.

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $226.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to development of bispecific antibodies and oncolytic virus therapies, expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, integration of digital platforms for patient monitoring and clinical trials. Major trends in the forecast period include rising adoption of immune checkpoint inhibitors across multiple cancer types, growth in development of cancer vaccines and adoptive cell therapies, increasing focus on personalized immuno-oncology treatments, expansion of hospital and ambulatory surgical center-based immunotherapy programs, rising clinical trials and research activities in monoclonal antibodies.

The escalating incidence of cancer cases is poised to accelerate the immuno-oncology drugs market ahead. Cancer involves rogue cells multiplying wildly, potentially metastasizing and disrupting bodily functions. This surge stems from aging demographics, lifestyle shifts, and sharper detection tools. Immuno-oncology drugs advance this landscape by rallying the immune system to hunt and destroy tumors, delivering potent, targeted options. For instance, in 2023, Cancer Australia, an Australia-based government agency, tallied 164,694 new diagnoses and 51,269 deaths, led by prostate, breast, melanoma, colorectal, and lung cancers; rare types claimed about one-third of cases and 42% of fatalities. Therefore, the increasing incidence of cancer cases is driving the growth of the immuno-oncology drugs market.

Leading companies in the immuno-oncology drugs market are teaming up to craft and launch cutting-edge checkpoint antibodies for superior cancer outcomes. Strategic collaborations spark breakthroughs via shared expertise, hastening combo therapies, custom care, and smart delivery methods. For instance, in March 2023, BioNTech SE, a Germany-based company, allied with OncoC4 Inc, a US-based pharmaceutical company, to jointly build and market a checkpoint antibody - the anti-CTLA-4 monoclonal contender ONC-392 - across diverse solid tumors.

In November 2023, AbbVie Inc., a US-based company, bought ImmunoGen for $10.1 billion. Through this acquisition, AbbVie seeks to broaden its lineup with ImmunoGen's immuno-oncology prowess. ImmunoGen Inc. is a US-based company that offers immune checkpoint inhibitors.

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the immuno-oncology drugs market by increasing the cost of imported biologics, monoclonal antibodies, and cancer vaccines, particularly affecting hospitals and clinics in North America, Europe, and Asia-Pacific regions. Segments like immune checkpoint inhibitors and adoptive cell transfer therapies are most impacted due to reliance on imported components and reagents. While tariffs have raised treatment costs and caused supply chain challenges, they have also encouraged domestic manufacturing, local R&D investment, and innovation in cost-effective immuno-oncology therapies.

The immuno-oncology drugs market research report is one of a series of new reports that provides immuno-oncology drugs market statistics, including immuno-oncology drugs industry global market size, regional shares, competitors with a immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immuno-oncology drugs are therapies that use medications to either enhance or suppress the immune system to help the body fight cancer, infections, and other diseases. They utilize naturally occurring or lab-produced compounds to strengthen the immune response and assist in identifying and eliminating cancer cells.

The main types of immuno-oncology drugs are monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are produced by cloning a single white blood cell, ensuring that all subsequent antibodies originate from the same parent cell. These drugs are applied in treating conditions such as melanoma, lung cancer, blood cancers, renal cell carcinoma, prostate cancer, bladder cancer, and others, and are used across hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.